Phase II year
1989
(last award dollars: 1990)
In Phase I, Athens Research and Technology, Inc. (ART) developed a prototype qualitative chromophoric assay that measures the functional levels of alpha-l-proteinase inhibitor (ALPI, also known as alpha-l-antitrypsin) in plasma or serum. This assay, which ART refers to as PI Diagnostic, is a rapid and simple visual test for determining individuals who have a genetic deficiency in ALPI. In its present form, the assay is performed on plasma and does not require instrumentation to determine functional level.In Phase II, ART plans to modify the PI Diagnostic with respect to sample material to be used in the assay and assay substrate. After optimizing the parameters, ART will perform efficacy tests to determine the reliability and accuracy of the PI Diagnostic in detecting individuals with ALPI deficiency. The ultimate goal is to develop an assay that will be inexpensive and convenient to use in a variety of laboratory settings (newborn screening, reference, hospital laboratories, and/or physician's office) and for alternate site testing.
Anticipated Results:Early diagnosis of ALPI deficiency could substantially reduce the number of people who develop emphysema.National Heart, Lung, And Blood Institute (NHLBI)